Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

178.75 +0.97 (+0.55%)

Streaming Delayed Price Updated: 1:52 PM EST, Dec 2, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

56 57 Next >

Biogen Inc. Surpasses Q3 Earnings And Revenue Estimates ↗

October 25, 2022

Biogen Inc. came out with quarterly earnings of $4.77 per share.

Via Talk Markets

Biogen Raises Annual Guidance Despite Q3 Earning Impacted By Biosimilar Competition ↗

October 25, 2022

Via Benzinga

Biogen Inches Higher On Third-Quarter Beat, But All Eyes Watch Alzheimer's Drug ↗

October 25, 2022

Biogen's partner, Eisai, will present Phase 3 results for lecanemab next month.

Via Investor's Business Daily

Recap: Biogen Q3 Earnings ↗

October 25, 2022

Biogen (NASDAQ:BIIB) reported its Q3 earnings results on Tuesday, October 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Biogen beat estimated earnings by...

Via Benzinga

Earnings Scheduled For October 25, 2022 ↗

October 25, 2022

Companies Reporting Before The Bell • UBS Gr (NYSE:UBS) is expected to report earnings for its third quarter. • SAP (NYSE:SAP) is expected to report earnings for its third quarter.

Via Benzinga

Where Biogen Stands With Analysts ↗

October 24, 2022

Over the past 3 months, 15 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Biogen Q3 Earnings Preview: Key Items For Investors To Watch ↗

October 24, 2022

Biogen Inc (NASDAQ: BIIB) is scheduled to report its third-quarter earnings on Tuesday during the premarket session amid cautious hope for its neurodegenerative disease programs and an ongoing

Via Benzinga

15 Analysts Have This to Say About Biogen ↗

October 24, 2022

Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:

Via Benzinga

Biogen To Report Q3 Earnings: Here's What To Expect ↗

October 21, 2022

Biogen will report third-quarter 2022 results on Oct 25, before market open.

Via Talk Markets

10 Health Care Stocks Whale Activity In Today's Session ↗

October 24, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today ↗

October 24, 2022

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.47% on an annualized basis producing an average annual return of 9.66%. Currently, Biogen has a market capitalization of...

Via Benzinga

Earnings Preview: Biogen ↗

October 24, 2022

Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-10-25. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an...

Via Benzinga

3 Alzheimer's Therapy Stocks to Invest in ↗

October 21, 2022

Alzheimer's treatments could make a big winner of these stocks.

Via The Motley Fool

This Beaten-Down ETF Is Still a Screaming Bear-Market Buy ↗

October 21, 2022

Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund.

Via The Motley Fool

Where Will Biogen Be in 5 Years? ↗

October 20, 2022

Is this biotech an investment worth buying and holding today?

Via The Motley Fool

FDA Pushes Extends Review For Biogen's Amyotrophic Lateral Sclerosis Drug ↗

October 17, 2022

Via Benzinga

Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate ↗

October 17, 2022

Via Benzinga

Biogen Whale Trades For October 20 ↗

October 20, 2022

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades.

Via Benzinga

Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients

October 20, 2022

Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which...

Via FinancialNewsMedia

10 Health Care Stocks Whale Activity In Today's Session ↗

October 19, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 18, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Biogen's Stock Pullback Offers a Second Chance

October 18, 2022

Biogen is positioned to become more diversified over time. A diminishing risk profile combined with emerging growth prospects make the stock attractive.

Via MarketBeat

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen

October 17, 2022

From Biogen Inc.

Via GlobeNewswire

This Is What Whales Are Betting On Biogen ↗

October 13, 2022

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available...

Via Benzinga

Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts ↗

October 13, 2022

Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's.

Via Benzinga

Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity ↗

October 13, 2022

Even a percentage of the Alzheimer's market could mean $7 billion for Biogen.

Via Investor's Business Daily

GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®

October 13, 2022

From GoodRx

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022 ↗

October 13, 2022

Upgrades

Via Benzinga

Elliott Wave Technical Analysis: Biogen, Inc. - Thursday, Oct. 13 ↗

October 13, 2022

Biogen Inc. is moving as predicted, looking for this pullback to this support as we have had a huge gap to the upside.

Via Talk Markets

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.